Advaxis, Inc. (NASDAQ:ADXS) – Investment analysts at Cantor Fitzgerald boosted their FY2018 EPS estimates for Advaxis in a research note issued to investors on Tuesday. Cantor Fitzgerald analyst M. Goldstein now anticipates that the biotechnology company will earn ($1.91) per share for the year, up from their prior estimate of ($2.28). Cantor Fitzgerald currently has a “Overweight” rating and a $5.00 price objective on the stock. Cantor Fitzgerald also issued estimates for Advaxis’ FY2019 earnings at ($1.96) EPS.
Advaxis (NASDAQ:ADXS) last announced its quarterly earnings data on Monday, March 12th. The biotechnology company reported ($0.49) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.55) by $0.06. Advaxis had a negative net margin of 940.64% and a negative return on equity of 149.14%. The firm had revenue of $2.06 million during the quarter, compared to analysts’ expectations of $3.03 million.
Several other brokerages have also recently commented on ADXS. ValuEngine upgraded shares of Advaxis from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. HC Wainwright set a $23.00 price objective on shares of Advaxis and gave the company a “buy” rating in a research note on Wednesday, December 27th.
Shares of Advaxis (NASDAQ:ADXS) remained flat at $$2.03 during midday trading on Friday. 114,373 shares of the stock traded hands, compared to its average volume of 1,207,814. Advaxis has a one year low of $1.75 and a one year high of $9.55. The stock has a market cap of $103.06, a price-to-earnings ratio of -0.86 and a beta of 1.06.
Several hedge funds and other institutional investors have recently made changes to their positions in ADXS. Wells Fargo & Company MN raised its position in Advaxis by 2.6% during the second quarter. Wells Fargo & Company MN now owns 44,813 shares of the biotechnology company’s stock worth $290,000 after acquiring an additional 1,144 shares during the last quarter. TIAA CREF Investment Management LLC raised its position in Advaxis by 2.4% during the second quarter. TIAA CREF Investment Management LLC now owns 98,164 shares of the biotechnology company’s stock worth $637,000 after acquiring an additional 2,329 shares during the last quarter. Northern Trust Corp raised its position in Advaxis by 4.4% during the second quarter. Northern Trust Corp now owns 456,817 shares of the biotechnology company’s stock worth $2,965,000 after acquiring an additional 19,434 shares during the last quarter. Vanguard Group Inc. raised its position in Advaxis by 7.2% during the second quarter. Vanguard Group Inc. now owns 1,782,990 shares of the biotechnology company’s stock worth $11,572,000 after acquiring an additional 119,980 shares during the last quarter. Finally, Dimensional Fund Advisors LP acquired a new position in Advaxis during the second quarter worth about $352,000. Hedge funds and other institutional investors own 29.79% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “FY2018 EPS Estimates for Advaxis, Inc. Lifted by Cantor Fitzgerald (ADXS)” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/03/16/fy2018-eps-estimates-for-advaxis-inc-lifted-by-cantor-fitzgerald-adxs.html.
Advaxis Company Profile
Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.